---
schema_version: "secwatch.filing_event.v1"
accession: "0000105770-24-000025"
form_type: "8-K"
ticker: "WST"
cik: "0000105770"
company_name: "WEST PHARMACEUTICAL SERVICES INC"
filed_at: "2024-04-25T23:59:59+00:00"
generated_at: "2026-06-03T07:20:39.037650+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# West Pharma Q1 sales $695.4M (-3%) adj EPS $1.56 (-21%), raises full-year adj EPS guidance

## Summary
- Reported-diluted EPS $1.55, down 16.2% YoY; adjusted-diluted EPS $1.56, down 21.2%.
- Net sales $695.4M, down 3.0% organically; Proprietary Products sales down 4.0%.
- Full-year 2024 net sales guidance reaffirmed at $3.000-3.025B; adjusted EPS guidance raised to $7.63-7.88 from $7.50-7.75.
- Board declares Q3 dividend $0.20/share, payable Aug 7, 2024 to holders of record Jul 31.
- Repurchased 729,679 shares for $267M at avg $365.87 in Q1.

## SEC filing metadata
- accession: 0000105770-24-000025
- form_type: 8-K
- ticker: WST
- cik: 0000105770
- company_name: WEST PHARMACEUTICAL SERVICES INC
- filed_at: 2024-04-25T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/105770/000010577024000025/0000105770-24-000025-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/105770/000010577024000025/wst-20240425.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000105770-24-000025
- JSON: https://secwatch.observer/filing/0000105770-24-000025.json
- Plain text: https://secwatch.observer/filing/0000105770-24-000025.txt

## Key facts
- Earnings Releases
  WEST PHARMACEUTICAL SERVICES INC reported first-quarter 2024 results: revenue 695.4 million, EPS 1.55.
  - Period: first-quarter 2024
  - Revenue: 695.4 million
  - EPS: 1.55
  - Result: reported results
  source text: Net sales of $695.4 million declined 3.0%; organic net sales also declined by 3.0%. • Reported-diluted EPS of $1.55 declined by 16.2%.
  evidence_url: https://www.sec.gov/Archives/edgar/data/105770/000010577024000025/0000105770-24-000025-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.